Biomaterials for a better life

Oligomedic title without plus-01.png
PLUS only.png

Oligo Medic was founded in 2010 by biomaterials experts with a mission to bring paradigm-changing healthcare products to market.

Management Team
jc_edited_edited_edited.png
Jerett Creed

Chief Executive Officer

IMG_6628_photoshopped.jpg
Abdellatif Chenite, PhD

Chief Technology Officer

ALBERTO%20(1)_edited.jpg
Alberto Restrepo, MD

Chief Medical Officer

SAM_edited_edited_edited_edited_edited.j
Sam A. Selmani, PhD

VP Product

Development

CYRIL_edited.jpg
Cyril Chaput, PhD, MBA

VP Regulatory Affairs/

Quality Assurance

MONIQUE_edited_edited.jpg
Monique Jarry

VP Finance/

Human Resources

Clinical Advisory Board
ALBERTO%20(1)_edited.jpg
Alberto Restrepo, MD
WDS Photo (1)_edited.png
William Stanish, MD
Schurhoff pic-2020_edited.png
Matthias Schurhoff, MD
Board of Directors
WhatsApp%20Image%202020-06-12%20at%205_edited.png

Amine Selmani, PhD - Founder, Executive Chairman

Dr. Selmani is the founder of Oligo Medic, his third orthopedic venture. He holds multiple patents on chitosan and derivatives thereof, for orthopedic applications. Dr. Selmani studied in Bordeaux University and has PhD in Material Sciences (1985) from the University of Montreal.  He is a former Professor at the engineering school, École Polytechnique de Montréal.  Dr. Selmani’s research in biomaterials and biotechnologies led him to incorporate BioSyntech in 1995 and be part of its executive team as CEO and Chairman of the Board for almost 10 years. During his tenure, Dr. Selmani took this biotechnology company public on both Nasdaq and TSX.

Also, Dr. Selmani founded in 1992 POLNOR (Polytechnique-Noranda), a large group of engineers and professionals, with the mandate to provide higher value to the Noranda amorphous selenium and other byproducts. Big funds coming from Noranda, Natural Sciences and Engineering Research Council of Canada, 3M and The Ecole Polytechnique de Montreal allowed the development of a high-resolution selenium-based direct X-ray detectors, specifically designed for full-field digital mammography used in most radiology centers in the world and commercialized by the well-known company in the field, Analogic. 

jc_edited_edited_edited.png

Jerett Creed - Chief Executive Officer

Mr. Creed has more than 20 years of MedTech experience with leadership roles in international commercialization, capital markets and business development. He has participated in M&A transactions exceeding $650M including two IPOs. Mr. Creed was founder and CEO of Cardigant Medical, a former public company, focused on the development and commercialization of novel peptide mimetics for treating vascular disease.  
Mr. Creed began his career with Johnson &  Johnson and spent more than a decade with the Company. Prior to assuming the role of CEO for Oligo Medic, Mr. Creed was in charge of launching JointRep throughout Latin America.  Mr. Creed holds a MS in Accounting and a BSc in Engineering, both from the University of Miami.

MONIQUE_edited.jpg

Monique Jarry - VP Finance & HR 

Ms Jarry holds a BA and MA (1991) from University of Montreal. She implemented many accounting systems in public companies listed in Nasdaq BB and on TSX. Ms. Jarry supervised all the financial aspects of a private investment company from 1992 until 2010, when she joined Oligomedic as a VP Finances. 

SAM_edited_edited_edited_edited_edited.j

Sam Alexandre Selmani, PhD - VP Product Development

Sam has been with Oligo Medic since 2016 and is leading the company's research & development efforts. During his time at Oligo, Sam has been involved in commercial and clinical development, manufacturing, and general management of the company. He has co-authored five patent applications covering basic polymer chemistry, hydrogels, nanoparticles and mechanical devices. Prior to that, Sam completed his Ph.D. in physics from McGill University, spending a year in Heidelberg, Germany. Sam is fluent in several languages.

1626548572828.jpg
Doreen Miao, PhD

Head of Commercialization